Capecitabine: key information and clinical applications of antineoplastic agents

Capecitabine is an oral chemotherapy drug mainly used to treat malignant tumors such as breast cancer and colorectal cancer. Its core advantage lies in targeted release of active ingredients and reduction of systemic side effects. This article will focus on its mechanism of action, indications, medication precautions and manufacturers, focusing on clinical value and safety.

Mechanism of action and therapeutic advantages

Capecitabine isprodrugs, which is enzymatically converted into 5-fluorouracil (5-FU) in the body, which exerts anti-tumor effects by interfering with DNA synthesis in cancer cells. Compared with intravenous chemotherapy, its oral administration method significantly improves patient compliance, andHigher drug concentrations in tumor tissue. Clinical data shows that the effective rate of single drug treatment for metastatic breast cancer is more than 30% (Reference: NCCN Guidelines).

Indications and combination treatment options

Currently approved indications include:First-line treatment for advanced breast cancer,Adjuvant chemotherapy for colorectal cancerandSecond-line treatment for gastric cancer. It is often used in combination with drugs such as docetaxel to enhance its efficacy. It should be noted that patients with liver dysfunction need to adjust the dosage. Common adverse reactions such as hand-foot syndrome can be alleviated by vitamin B6 (data source: FDA drug instructions).

Medication safety and production information

Blood routine and liver and kidney function need to be monitored regularly during treatment. Major domestic manufacturers include:

Summary and Outlook

As a representative drug for targeted tumor therapy, capecitabine balances efficacy and safety, and its oral dosage form provides the possibility of home treatment. In the future, with the optimization of personalized dosing regimens, more cancer patients will benefit from survival. Please strictly follow medical advice before use, refer toNational Health Commission's "Guidelines for the Clinical Application of Anti-Tumor Drugs"Standardize medication.

Quote sources:
1. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines 2023 Edition
2. FDA approved drug package insert (NDA 020896)
3. Roche Pharmaceuticals Xeloda Product Manual
4. Hengrui Medicine Aiheng Instructions (National Drug Approval No. H20193245)